On the stock market since 2004, it operates in the world of health and science. It has 27 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 25% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 45 buys and 43 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $28.00 — 5,217% above today’s price.
A loss of $39.5M against $785K in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.53. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, ONCT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ONCT is a small company that closed last year at a loss. The road back to profit runs through spending discipline.